NasdaqGS:PCVXBiotechs
Vaxcyte (PCVX) On Tighter Phase 3 Timing And New Hires Looks Undervalued
Vaxcyte (PCVX) has given investors two fresh data points to consider. The company provided more specific timing for key VAX-31 Phase 3 readouts and added senior leaders for medical and legal oversight.
Recent trading has been choppy, with a 1-day share price return of 0.97% and a 7-day share price decline of 2.76%. However, Vaxcyte’s 90-day share price return of 25.31% alongside a 1-year total shareholder return of 84.86% points to momentum that has been building rather than fading as...